Improving immunoassay detection accuracy of anti-SARS-CoV-2 antibodies through dual modality validation

Biosens Bioelectron X. 2022 Sep:11:100176. doi: 10.1016/j.biosx.2022.100176. Epub 2022 Jun 5.

Abstract

A novel test strategy is proposed with dual-modality detection techniques for COVID-19 antibody detection. The full-length S protein of SARS-CoV-2 was chemically immobilized on a glass surface to capture anti-SARS-CoV-2 IgG in patient serum and was detected through either Electrochemical Impedance Spectroscopy (EIS) or fluorescence imaging with labeled secondary antibodies. Gold nanoparticles conjugated with protein G were used as the probe and the bound GNP-G was detected through EIS measurements. Anti-human-IgG conjugated with the fluorescent tag Alexa Fluor 488 was used as the probe for fluorescence imaging. Clinical SARS-CoV-2 IgG positive serum and negative controls were used to validate both modalities. For fluorescence-based detection, a high sensitivity was noticed with a quantification range of 0.01-0.1 A.U.C. and a LOD of 0.004 A.U.C. This study demonstrates the possibility of utilizing different measurement techniques in conjunction for improved COVID-19 serology testing.

Keywords: Anti-SARS-CoV-2 IgG; COVID-19; Electrochemical impedance spectroscopy (EIS); Fluorescence labeling; Serology testing.